As the COVID-19 pandemic continues to affect us all, BioLegend is here to help the scientific community with our products, resources, and support. We understand that science is critical for finding solutions to the current situation. BioLegend is committed to supporting researchers in their efforts to characterize all aspects of the SARS-CoV-2 virus and COVID-19 disease, including the development of novel therapeutics. Our reagents are being employed in several research areas, including:
- Characterization of the immune response in COVID-19 patients and disease models
- The development and validation of viral detection kits
- Therapeutics response monitoring
- Monitoring vaccine candidates
- Discovery of virus-associated host biomarkers
To make it easier to find what you need, we’ve compiled our relevant products based on workflow. BioLegend is here to partner with you and your teams, so if you can’t find a specific product or require a custom reagent, please reach out. Together, we can find a solution.
Please note: BioLegend is deemed an essential business and is operational. If you’re looking for more information regarding our operations during this time, read a message from our CEO and find answers to our most frequently asked questions.
BioLegend wants to help in your fight against COVID-19
BioLegend is ready to collaborate with your organization to help you accelerate the development of diagnostic tests, therapeutics, and vaccines for SARS-CoV-2, and be a partner in your research. Please tell us how we can support your work.
In order for viruses to infect a host cell, they first must recognize a protein or receptor on the host cell surface. This process is called viral recognition. In the case of SARS-CoV-2, which causes the disease COVID-19, the virus recognizes the enzyme ACE2. Specifically, the S1 spike protein of SARS-CoV-2 binds the enzymatic domain of ACE2. Once S1 and ACE2 interact, the virus enters the host cell, mediated by the TMPRSS2 protease. BioLegend provides specific SARS-CoV-2 and host recombinant proteins and antibodies to help investigate this step of the disease.
SARS-CoV-2 causes the disease COVID-19, which can result in inflammation. We provide a number of tools for researchers to detect and characterize this inflammation. Our ELISA Sets and Kits are trusted to accurately quantitate cytokine and chemokine levels, while our LEGENDplex™ kits offer a flow cytometry-based method to analyze up to 13 different targets simultaneously.
The cellular response to SARS-CoV-2 is key to the induced cytokines, inflammation, and recovery. Players include CD8+ T cells that possess potent cytotoxic abilities, and CD4+ Th1 cells that are known for their role in supporting anti-viral immunity and sparking an adaptive immune response. We provide reliable reagents for phenotyping and isolating cell populations of interest, including T cells, B cells, NK cells, monocytes, and more.
Understanding the anti-viral signaling pathways that respond to infection by SARS-CoV-2 is critical to the development of novel therapeutics. We offer many antibodies to detect important mediators involved in immune pathways. These include recognition of viral pathogens by Toll-like receptors, downstream signaling through STAT and NF-κB signaling, and ultimately, the production of interferons through IRF-mediated transcription. Our anti-viral pathway reagents have been validated across a variety of applications, including western blotting, flow cytometry, functional assays, ChIP, and microscopy.
